Newsroom

NEW YORK--(BUSINESS WIRE)--JPMorgan Chase & Co. (NYSE: JPM) (“JPMorganChase” or the “Firm”) declared a quarterly dividend on the outstanding shares of the common stock of JPMorganChase. Information can be found on the Firm’s Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $362 b...

COLUMBIA, Tenn.--(BUSINESS WIRE)--First Farmers and Merchants Corporation (OTCID: FFMH), the holding company for First Farmers and Merchants Bank, today announced that its Board of Directors has declared the Company’s regular quarterly cash dividend of $0.29 per share, which will be paid on April 16, 2026, to shareholders of record as of April 1, 2026. The dividend represents a 7.4% increase compared with the cash dividend paid during the same period last year. About First Farmers and Merchants...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women’s Cancers. Additional abstracts accepted for presentation will also be shar...

NEW YORK--(BUSINESS WIRE)--As previously announced, JPMorgan Chase & Co. (NYSE: JPM) (“JPMorganChase” or the “Firm”) will host a conference call to review first-quarter 2026 financial results on Tuesday, April 14, 2026 at 8:30 a.m. (ET). The results are scheduled to be released at approximately 7:00 a.m. (ET). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorganChase will notify the public th...

CINCINNATI--(BUSINESS WIRE)--Today, Fifth Third Bancorp announced the declaration of cash dividends on its common shares, Series H preferred shares, Series I preferred shares, Series J preferred shares, Series K preferred shares, Series M preferred shares, and Class B Series A preferred shares. Fifth Third Bancorp (Nasdaq: FITB) today declared a cash dividend on its common shares of $0.40 per share for the first quarter of 2026. The dividend is payable on April 15, 2026 to shareholders of recor...

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX : KXS), leader mondial de l'orchestration de la chaîne d'approvisionnement, a annoncé aujourd'hui une nouvelle étape importante dans l'optimisation à grande échelle des chaînes d'approvisionnement au sein de la plateforme Kinaxis Maestro™. Maestro assure déjà une optimisation haute performance des chaînes d'approvisionnement mondiales complexes, et Kinaxis renforce désormais son leadership grâce à l'accélération GPU alimentée par NVIDIA cuOpt...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization...

WASHINGTON--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), empresa líder internacional en salud de la mujer, ha publicado hoy unos datos que revelan que, aunque las pruebas de detección de algunas enfermedades han aumentado entre las mujeres de todo el mundo, sigue existiendo una gran brecha en materia de cribado. Más de la mitad de las mujeres y niñas de 15 años o más, lo que supone aproximadamente 1 500 millones de mujeres, no se sometieron a pruebas de detección de cáncer, hipertensión, diab...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (A...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented in an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, CA from April 17 - 22, 2026. In this now fully enrolled study, STK-012 is being evaluated in combinatio...